Table 1.
Patient characteristics in the two groups based on SARS-CoV-2 non-infected and infected patients with hematological malignancies. Comparisons between SARS-CoV-2 infected versus uninfected patients were performed using unpaired Student t-tests and Fisher exact tests, respectively, for quantitative and qualitative variables.
| No CoV-2 infection. n = 31 |
CoV-2 infection. n = 16 |
|||||||
|---|---|---|---|---|---|---|---|---|
| Characteristics | n | (%) | n | (%) | n | (%) | p value | |
| Gender | ||||||||
| Female | 24 | 51.1 | 15 | 48.4 | 9 | 56.3 | 0.760 | |
| Male | 23 | 48.9 | 16 | 51.6 | 7 | 43.7 | ||
| Age (years). mean ± SEM | 63.3 ± 17.1 | 66.9 ± 13.9 | 57.5 ± 19.8 | 0.013 | ||||
| range (18–92) | ||||||||
| Number of anti CoV-2 vaccine shots. mean ± SEM | range (2–4) | 3.4 ± 0.6 | 3 ± 0.7 | 3 ± 0.7 | 0.723 | |||
| Anti CoV-2 vaccination boost* | 34 | 72.3 | 21 | 67.7 | 13 | 81.3 | 0.494 | |
| Hematological malignancies | 0.940 | |||||||
| B cell non Hodgkin lymphoma | 21 | 44.8 | 13 | 42 | 8 | 50 | ||
| Hodgkin lymphoma | 8 | 17.0 | 5 | 16.1 | 3 | 18.7 | ||
| Multiple myeloma | 8 | 17.0 | 5 | 16.1 | 3 | 18.7 | ||
| Acute myeloid leukemia | 5 | 10.6 | 4 | 12.9 | 1 | 6.3 | ||
| Others | 5 | 10.6 | 4 | 12.9 | 1 | 6.3 | ||
| Ongoing therapy | 0.736 | |||||||
| Chemotherapy | 16 | 34.0 | 11 | 35.5 | 5 | 31.3 | ||
| Chemotherapy + Rituximab | 15 | 31.9 | 10 | 32.2 | 5 | 31.3 | ||
| Daratumumab based regimen | 7 | 14.9 | 4 | 12.9 | 3 | 18.7 | ||
| Rituximab alone | 6 | 12.8 | 3 | 9.7 | 3 | 18.7 | ||
| Others | 3 | 6.4 | 3 | 9.7 | 0 | 0 | ||
| Cancer status at vaccination | Controlled disease | 39 | 82.9 | 26 | 83.9 | 13 | 81.3 | 0.821 |
| Uncontrolled disease | 8 | 17.1 | 5 | 16.1 | 3 | 18.7 | ||
| Known COVID19 infection before vaccination | 3 | 6.4 | 1 | 3.2 | 2 | 12.5 | 0.264 | |
| CoV-2 infection characteristics | ||||||||
| time from last vaccine injection, month. mean ± SEM | 2.59 ± 2.70 | |||||||
| delta CoV-2 | 6 | 37.5 | ||||||
| omicron CoV-2 | 10 | 62.5 | ||||||